The utility of cost discussions between patients with cancer and oncologists

American Journal of Managed Care

Volumn 21, Issue 9, 2015, Pages 607-615

  Zafar, S Yousuf ^a   Chino, Fumiko ^b   Ubel, Peter A ^c   Rushing, Christel ^b   Samsa, Gregory ^b   Altomare, Ivy ^a   Nicolla, Jonathan ^b   Schrag, Deborah ^d   Tulsky, James A ^d   Abernethy, Amy P ^a   Peppercorn, Jeffery M ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c DUKE UNIVERSITY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER HORMONE THERAPY; CANCER PATIENT; COST CONTROL; COST OF ILLNESS; COST UTILITY ANALYSIS; CROSS-SECTIONAL STUDY; DISTRESS SYNDROME; DOCTOR PATIENT RELATION; FEMALE; FINANCIAL DEFICIT; FOLLOW UP; HEALTH CARE COST; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; ONCOLOGIST; PATIENT PREFERENCE; PATIENT REFERRAL; PRIORITY JOURNAL; QUALITY OF LIFE; RACE DIFFERENCE; SELF EVALUATION; SOLID TUMOR; TREATMENT DURATION; DECISION MAKING; ECONOMICS; FINANCIAL MANAGEMENT; INTERPERSONAL COMMUNICATION; MIDDLE AGED; NEOPLASMS; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CANCER CARE FACILITIES; COMMUNICATION; CROSS-SECTIONAL STUDIES; DECISION MAKING; FEMALE; FINANCING, PERSONAL; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ONCOLOGISTS; PATIENT PREFERENCE; PHYSICIAN-PATIENT RELATIONS; SOCIOECONOMIC FACTORS; TIME FACTORS;

EID: 84941949515     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-128.
2. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14(12):1165-1174.
3. Cutler DM, Sahni NR. If slow rate of health care spending growth persists, projections may be off by $770 billion. Health Aff (Millwood). 2013;32(5):841-850.
4. Guy GP Jr, Ekwueme DU, Yabroff KR, et al. Economic burden of cancer survivorship among adults in the United States. J Clin Oncol. 2013;31(30):3749-3757.
5. Despite health law's protections, many consumers may be 'uninsured'. Kaiser Health News website, http://khn.org/news/michelleandews-health-law-protections-consumers/. Published 2013. Accessed August 24, 2015.
6. Shankaran V, Jolly S, Blough D, Ramsey SD. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol. 2012;30(14):1608-1614.
7. Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013;18(4):381-390.
8. Ubel PA, Abernethy AP, Zafar SY. Full disclosure-out-of-pocket costs as side effects. N Engl J Med. 2013;369(16):1484-1486.
9. Ramsey S, Blough D, Kirchhoff A, et al. Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013;32(6):1143-1152.
10. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306-311.
11. Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29(18):2534-2542.
12. Meropol NJ, Schrag D, Smith TJ, et al; American Society of Clinical Oncology. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009;27(23):3868-3874.
13. Ganz PA, Levit LA. Charting a new course for the delivery of highquality cancer care. J Clin Oncol. 2013;31(36):4485-4487.
14. Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367(17):1616-1625.
15. Smith SK, Zimmerman S, Williams CS, et al. Post-traumatic stress symptoms in long-term non-Hodgkin's lymphoma survivors: does time heal? J Clin Oncol. 2011;29(34):4526-4533.
16. Protocol and instruments requests. Cancer Care Outcomes Research and Surveillance Consortium website. https://www.cancors.org/. Published 2013. Accessed August 24, 2015.
17. Prawitz AD, Garman ET, Sorhaindo B, et al. InCharge Financial Distress/Financial Well-Being Scale: development, administration, and score interpretation. Financ Counsel Planning. 2006;17(1):34-50.
18. Locke DE, Decker PA, Sloan JA, et al. Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients. J Pain Symptom Manage. 2007;34(6):628-638.
19. Zullig LL, Peppercorn JM, Schrag D, et al. Financial distress, use of cost-coping strategies, and adherence to prescription medication among patients with cancer [published online August 20, 2013]. J Oncol Pract. doi: 10.1200/JOP.2013.000971.
20. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med. 2011;364(21):2060-2065.
21. Schnipper LE, Meropol NJ, Brock DW. Value and cancer care: toward an equitable future. Clin Cancer Res. 2010;16(24):6004-6008.
22. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933-980.
23. Alexander GC, Casalino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. JAMA. 2003;290(7):953-958.
24. Neumann PJ, Palmer JA, Nadler E, Fang C, Ubel P. Cancer therapy costs influence treatment: a national survey of oncologists. Health Aff (Millwood). 2010;29(1):196-202.
25. Schrag D, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007;25(2):233-237.
26. Alexander GC, Casalino LP, Tseng CW, McFadden D, Meltzer DO. Barriers to patient-physician communication about out-of-pocket costs. J Gen Intern Med. 2004;19(8):856-860.
27. Rosenthal JA, Lu X, Cram P. Availability of consumer prices from US hospitals for a common surgical procedure. JAMA Intern Med. 2013;173(6):427-432.
28. DeNavas-Walt C, Proctor BD, Smith JC. Income, poverty, and health insurance coverage in the United States: 2012. US Census Bureau website. https://www.census.gov/prod/2013pubs/p60-245.pdf. Published September 2013. Accessed August 24, 2015.
29. Bernard DS, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol. 2011;29(20):2821-2826.
30. Mack JW, Paulk ME, Viswanath K, Prigerson HG. Racial disparities in the outcomes of communication on medical care received near death. Arch Intern Med. 2010;170(17):1533-1540.
31. Gordon HS, Street RL Jr, Sharf BF, Souchek J. Racial differences in doctors' information-giving and patients' participation. Cancer. 2006;107(6):1313-1320.
32. Gordon HS, Street RL Jr, Sharf BF, Kelly PA, Souchek J. Racial differences in trust and lung cancer patients' perceptions of physician communication. J Clin Oncol. 2006;24(6):904-909.
33. Institute of Medicine. Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis. The National Academies Press website. http://www.nap.edu/catalog.php?record-id=18359. Published 2013. Accessed January 9, 2014.
34. Davidoff AJ, Erten M, Shaffer T, et al. Out-of-pocket health care expenditure burden for medicare beneficiaries with cancer. Cancer. 2013;119(6):1257-1265.